

ASX Release

13th September 2016

Capsule-Reformulated MPL now shipped to centres in NSW and Queensland for evaluation against canine cancers

PharmAust Limited ("PharmAust" or "the Company") (ASX: PAA) is pleased to announce that it has added two centres to its canine cancer trial and has now shipped 2 x 1,000 newly formulated capsules containing MPL to enable the trials to begin at the Animal Referral Hospital at Homebush, NSW and at Queensland Veterinary Specialists, Brisbane, QLD. The capsules will be administered by owners to their pet dogs and measurements of tumour regression or progression will be undertaken during regular visits to the surgery. The outcome of these studies in addition to the evaluation of MPL capsules at the University of Cambridge, Cambridge UK will be an important step as regards PharmAust's Option agreement with Novartis Animal Health.

PharmAust will advise shareholders when the trials at the different centres begin.

In the USA, initial pet cancer diagnosis can cost between \$1,000 and \$2,000. A standard course of chemotherapy costs between \$3,000 and \$5,000, and radiation treatments used for brain and nasal tumours run between \$6,000 and \$10,000. Costs vary by region and the type of cancer, among other factors). There are nearly 80 million pet dogs in the USA.

***References:**

2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.

American pet products manufacturers association, Inc. 2011-2012 National pet owner's survey
<http://www.cbsnews.com/news/the-heartbreak-and-high-costs-of-pet-cancer/>

For further details, please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Mr Robert Bishop
Executive Director
Tel: 0417 445 180
robertbishop@pharmaust.com